N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
Sandhoff disease involves the CNS accumulation of ganglioside GM2 and asialo-GM2 (GA2) due to inherited defects in the beta-subunit gene of beta-hexosaminidase A and B (Hexb gene). Accumulation of these glycosphingolipids (GSLs) produces progressive neurodegeneration, ultimately leading to death. Su...
Main Authors: | Baek, R, Kasperzyk, J, Platt, F, Seyfried, T |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2008
|
Similar Items
-
N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal sandhoff diseased mice
by: Baek, R, et al.
Published: (2004) -
Substrate reduction therapy reduces brain ganglioside GM2 in neonatal Sandhoff disease mice
by: Baek, R, et al.
Published: (2005) -
N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis.
by: Kasperzyk, J, et al.
Published: (2004) -
N-butyldeoxygalactonojirimycin reduces postnatal cerebellar ganglioside content in a mouse model of GM1 gangliosidosis
by: Kasperzyk, J, et al.
Published: (2004) -
Substrate deprivation therapy reduces brain ganglioside content and GM1 in neonatal storage disease mice
by: Kasperzyk, J, et al.
Published: (2002)